PHARMENA SA

  • Market Cap: N/A
  • Industry: FMCG
  • ISIN: PLPHRMN00011
PLN
3.45
-0.02 (-0.58%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

FMCG

stock-summary
Market cap

PLN 39 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.91

stock-summary
Return on Equity

-14.34%

stock-summary
Price to Book

3.32

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2024)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.99%
0%
2.99%
6 Months
-4.17%
0%
-4.17%
1 Year
-23.33%
0%
-23.33%
2 Years
-48.2%
0%
-48.2%
3 Years
-42.31%
0%
-42.31%
4 Years
-53.38%
0%
-53.38%
5 Years
-69.6%
0%
-69.6%

PHARMENA SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-51.62%
EBIT Growth (5y)
9.46%
EBIT to Interest (avg)
-3.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
2.25
Tax Ratio
31.25%
Dividend Payout Ratio
32.71%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
23.51%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.18
EV to EBIT
-8.43
EV to EBITDA
-8.73
EV to Capital Employed
26.03
EV to Sales
26.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-309.01%
ROE (Latest)
-14.34%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is -100.00% vs 0.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 44.44% vs -550.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-0.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.50",
          "val2": "-0.90",
          "chgp": "44.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-30,954.50%",
          "val2": "-4,729.70%",
          "chgp": "-2,622.48%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs -98.03% in Dec 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 619.23% vs -13.04% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.70",
          "val2": "-3.20",
          "chgp": "-15.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.70",
          "chgp": "-28.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "27.00",
          "val2": "-5.20",
          "chgp": "619.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,448.20%",
          "val2": "-12,638.80%",
          "chgp": "-80.94%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQstock-summary

Sep'24
Jun'24
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-0.70
-0.70
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.50
-0.90
44.44%
Operating Profit Margin (Excl OI)
-30,954.50%
-4,729.70%
-2,622.48%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2024 is -100.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is 44.44% vs -550.00% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'23stock-summary

Dec'23
Dec'22
Change(%)
Net Sales
0.30
0.30
Operating Profit (PBDIT) excl Other Income
-3.70
-3.20
-15.62%
Interest
0.50
0.70
-28.57%
Exceptional Items
-0.00
-0.20
100.00%
Consolidate Net Profit
27.00
-5.20
619.23%
Operating Profit Margin (Excl OI)
-13,448.20%
-12,638.80%
-80.94%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs -98.03% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 619.23% vs -13.04% in Dec 2022

stock-summaryCompany CV
About PHARMENA SA stock-summary
stock-summary
PHARMENA SA
FMCG
Pharmena SA is a Poland-based producer of cosmetics and pharmaceuticals. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.
Company Coordinates stock-summary
Company Details
Ul. Wolczanska 178 , LODZ None : 90-530
stock-summary
Tel: 48 42 291337048 502 258387
stock-summary
Registrar Details